Overview

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who are undergoing surgery for stage IB, stage II, or stage IIIA non-small cell lung cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Vaccines